Exagen Inc. (XGN) Key Metrics

NASDAQ: XGNValuation, returns, debt and efficiency ratios over 10 years.

XGN valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$187.0M
Enterprise value
$208.6M
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
2.6
10-yr median 2.0
Price / book
17.0
10-yr median 4.0
EV / EBITDA
—
Dividend yield
—
Beta
2.12

XGN key metrics, 2015–2025

Fiscal year ended December 31, 2025 · U.S. dollars

XGN valuation Price multiples at each fiscal year-end price.

Price / sales+46.8%
2.0
2025 · hover or tap a bar for each year
2019: 7.92020: 4.0 (−49.6%)2021: 3.8 (−3.3%)2022: 0.9 (−76.6%)2023: 0.7 (−25.6%)2024: 1.3 (+100.3%)2025: 2.0 (+46.8%)
20152025
Price / book−4.0%
7.5
2025 · hover or tap a bar for each year
2019: 5.72020: 4.0 (−30.4%)2021: 2.2 (−45.2%)2022: 1.0 (−55.9%)2023: 1.6 (+60.6%)2024: 7.8 (+404.6%)2025: 7.5 (−4.0%)
20152025
Free cash flow yield+7.6 pts
−10.9%
2025 · hover or tap a bar for each year
2019: −3.2%2020: −8.7% (−5.5 pts)2021: −12.2% (−3.5 pts)2022: −88.9% (−76.7 pts)2023: −43.5% (+45.5 pts)2024: −18.5% (+25.0 pts)2025: −10.9% (+7.6 pts)
20152025

XGN valuation history

Fiscal year-endToday10-year median

XGN returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

XGN debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

XGN cash returned to shareholders

DividendsBuybacksFree cash flow

XGN price vs earnings per share

Share price at year-endEPS (right axis)

XGN key metrics

2015–2025
Exagen Inc. key metrics by fiscal year
2025202420232022202120202019201820172015
Valuation
Market capitalization$131.1M$74.6M$35.2M$41.0M$185.8M$167.0M$319.0M———
Enterprise value$124.6M$75.8M$21.9M$13.8M$114.4M$136.5M$273.1M———
Price / sales2.01.30.70.93.84.07.9———
Price / book7.57.81.61.02.24.05.7———
EV / sales1.91.40.40.32.43.36.8———
Earnings yield−15.2%−20.3%−67.3%−115.6%−14.5%−10.0%−3.8%———
Free cash flow yield−10.9%−18.5%−43.5%−88.9%−12.2%−8.7%−3.2%———
Dividend yield——28.2%—0.2%0.1%2.1%———
Shareholder yield (dividends + buybacks)—0.0%28.2%0.6%0.2%0.1%2.1%———
Share price at fiscal year-end$6.08$4.10$1.99$2.40$11.63$13.20$25.40———
Per share
Revenue per share$3.09$3.06$2.97$2.67$3.02$3.32$3.22———
Earnings per share−$0.93−$0.83−$1.34−$2.77−$1.68−$1.32−$0.96———
Operating cash flow per share−$0.63−$0.73−$0.82−$1.88−$1.27−$1.11−$0.77———
Free cash flow per share−$0.66−$0.76−$0.86−$2.13−$1.42−$1.15−$0.81———
Cash per share$1.49$1.21$2.06$3.65$6.23$4.54$5.74———
Book value per share$0.81$0.52$1.28$2.49$5.32$3.31$4.43———
Tangible book value per share$0.81$0.52$1.28$2.49$4.63$2.44$3.55———
Dividends per share——$0.56—$0.02$0.01$0.54———
Capex per share$0.03$0.03$0.05$0.25$0.15$0.04$0.03———
Debt per share$1.19$1.27$1.31$2.06$1.76$2.13$2.08———
Shares outstanding21.6M18.2M17.7M17.1M16.0M12.7M12.6M———
Change in shares outstanding+18.4%+3.0%+3.5%+7.0%+26.2%+0.7%————
Returns & profitability
Return on equity (ROE)−147.8%−93.8%−72.7%−74.4%−42.4%−34.2%−49.2%———
Return on invested capital (ROIC)−102.7%−107.0%−146.1%−252.4%−152.6%−114.1%−101.6%−99.4%−297.1%—
Return on assets (ROA)−38.8%−29.7%−33.1%−45.2%−26.6%−20.0%−20.5%−32.5%−146.4%−120.7%
Return on tangible assets−34.4%−33.8%−41.6%−55.0%−23.9%−24.8%−15.6%−34.3%−173.9%−222.9%
Free cash flow margin−21.4%−24.8%−29.1%−80.0%−46.9%−34.6%−25.0%−29.3%−43.0%−70.8%
Financial health
Total debt$25.7M$23.2M$23.2M$35.2M$28.1M$27.0M$26.1M$24.7M$18.8M$25.9M
Cash & short-term investments$32.2M$22.0M$36.5M$62.4M$99.4M$57.4M$72.1M$13.2M$11.2M$2.5M
Net debt−$6.5M$1.2M−$13.3M−$27.2M−$71.4M−$30.5M−$46.0M$11.5M$7.6M$23.4M
Debt / equity1.472.431.020.830.330.640.47———
Debt / assets0.440.520.410.410.230.340.300.850.921.77
Current ratio3.452.704.027.5512.108.0413.782.382.660.11
Quick ratio3.452.703.787.3611.987.9013.542.272.550.11
Interest coverage-3.3-6.1-9.8-18.8-9.2-5.9-2.7-1.7-2.7-2.3
Working capital$34.7M$22.9M$35.9M$63.0M$103.4M$61.7M$75.4M$12.4M$8.3M−$31.1M
Invested capital$10.9M$10.7M$9.4M$15.3M$13.6M$11.4M$9.7M$4.8M$3.0M$1.2M
Tangible asset value$17.4M$9.5M$22.7M$42.5M$73.9M$30.8M$44.6M−$12.2M−$10.3M−$28.2M
Net current asset value$8.3M$1.3M$13.6M$28.9M$74.2M$34.0M$48.6M−$14.3M−$11.8M−$32.9M
Graham net-net per share−$0.01−$0.40$0.49$1.41$4.30$2.23$3.54———
Capital allocation
Dividends paid——$9.9M—$390,000$142,000$6.7M$0$0$0
Share buybacks (net)—$0$0$239,000$0$0$0$0$0$0
Capex / revenue1.0%0.9%1.6%9.5%4.9%1.1%1.0%0.6%2.1%4.5%
Capex / depreciation0.300.300.382.772.500.830.680.270.850.92
Stock-based compensation / revenue3.2%3.2%6.9%10.3%9.8%6.4%1.4%0.4%0.7%1.6%
R&D / revenue9.4%9.7%9.3%21.7%15.0%8.5%5.4%6.6%5.8%7.6%
SG&A / revenue70.0%74.4%90.3%114.2%92.2%88.2%71.1%60.7%70.2%97.0%
Efficiency
Days sales outstanding51.247.243.963.070.163.652.736.98.2—
Days of inventory on hand——36.921.820.329.023.818.67.0—
Days payables outstanding54.558.948.841.748.849.526.736.251.077.0
Cash conversion cycle (days)-3.2-11.731.943.041.743.149.819.3-35.8—
Receivables turnover7.127.748.325.795.205.746.929.9044.38—
Payables turnover6.706.207.488.747.487.3813.6510.087.154.74
Inventory turnover——9.9016.7817.9512.5915.3619.6451.97—
Asset turnover1.301.090.730.430.480.500.691.321.531.13
Average receivables$9.3M$7.2M$6.3M$7.9M$9.3M$7.3M$5.8M$3.3M$604,000—
Average payables$4.1M$3.6M$3.1M$2.8M$2.8M$2.2M$1.4M$1.5M$2.0M$2.0M
Average inventory——$2.3M$1.4M$1.1M$1.3M$1.2M$783,000$272,000$0
Intangibles / total assets0.0%0.0%0.0%0.0%8.9%14.1%12.5%19.1%27.7%41.2%

Computed from XGN's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

XGN valuation and financial ratios

Exagen earned a return on equity of −147.8% and a return on invested capital of −102.7% in fiscal 2025. It ended the year with $25.7 million of debt and $32.2 million in cash and short-term investments, a net cash position of $6.5 million.

See the XGN income statement, the XGN chart for price history, or the XGN stock overview for the latest quote and news.

XGN key metrics FAQ

What is Exagen's return on equity?

Exagen's return on equity (ROE) was −147.8% in fiscal 2025: net income of -$20.0 million on average shareholders' equity of $13.5 million.

What is Exagen's ROIC?

Exagen's return on invested capital was −102.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Exagen have?

Exagen had total debt of $25.7 million at the end of fiscal 2025, a debt-to-equity ratio of 1.47 and more cash than debt.

What is Exagen's free cash flow yield?

Exagen generated -$14.3 million of free cash flow in fiscal 2025, a free cash flow yield of −10.9% on its market value at year-end ($131.1 million).

What is Exagen's current ratio?

Exagen's current ratio was 3.45 at the end of fiscal 2025: current assets were 3.45 times current liabilities.

Diagnostics & Research key metrics